Provider Newsflash
December, 2021

Company Announcement/Recall – Sandoz, Inc. Enoxaparin

Purpose of this communication:

We are writing to inform you that the FDA has posted a nationwide voluntary recall initiated by Sandoz, Inc. of their Enoxaparin Sodium Injection, USP 40 mg/0.4 ml single-dose syringes, Lot SAB06761A distributed to the consumer in September and October, 2021. A portion of the lot experienced a temperature excursion during shipment. The exposure to higher temperatures may have significantly impacted the product's effectiveness, and thus, there may be reasonable probability of risk for patients with health conditions that the product is intended to treat.

What do I need to do?

- Please review the following recall notice: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/sandoz-inc-issues-nationwide-recall-one-lot-enoxaparin-sodium-injection-usp-40mg04-ml-due?utm_medium=email&utm_source=govdelivery
- Notify impacted patients and facilitate the repair, replacement and/or resolution of the recall, according to the guidelines issued by the manufacturer in the notification.
- Confirm if you have any CareCentrix patients affected by this recall and notify the CareCentrix Quality Department by faxing information to: 919-792-6718 Attn: Quality Department.

Thank you in advance for your cooperation and continued partnership.